Kane JM, et al. - Researchers analyzed patients (aged 18–35 years) with a DSM-5 diagnosis of schizophrenia and less than 5 years of lifetime antipsychotic use in order to document the acceptability of treatment with long-acting injectable (LAI) antipsychotic medication to these patients as demonstrated by enrollment in a cluster-randomized LAI clinical trial. From 19 US outpatient clinics randomized to provide LAI antipsychotic treatment, 576 potential participants were identified. Among these, declination to participation by some patients resulted in 328 providing written study consent. Among early-phase patients with schizophrenia, large proportion showed a willingness to participate in an LAI antipsychotic trial and by inference in non-study LAI antipsychotic treatment. Observations suggest a substantial enhancement in the use of LAI antipsychotics could be achieved by employing LAI antipsychotic–focused staff training. Acceptance